Request for Nominations of Candidates To Serve on the Advisory Committee on Breast Cancer in Young Women (ACBCYW), 80945-80946 [2011-33092]
Download as PDF
<![CDATA[
80945
Federal Register / Vol. 76, No. 248 / Tuesday, December 27, 2011 / Notices
Notice is hereby given that
the Federal Deposit Insurance
Corporation (Corporation) has been
appointed the sole receiver for the
following financial institutions effective
as of the Date Closed as indicated in the
listing. This list (as updated from time
to time in the Federal Register) may be
relied upon as ‘‘of record’’ notice that
the Corporation has been appointed
receiver for purposes of the statement of
policy published in the July 2, 1992
issue of the Federal Register (57 FR
SUMMARY:
FEDERAL DEPOSIT INSURANCE
CORPORATION
Update to Notice of Financial
Institutions for Which the Federal
Deposit Insurance Corporation Has
Been Appointed Either Receiver,
Liquidator, or Manager
Federal Deposit Insurance
Corporation.
ACTION: Update Listing of Financial
Institutions in Liquidation.
AGENCY:
29491). For further information
concerning the identification of any
institutions which have been placed in
liquidation, please visit the Corporation
Web site at www.fdic.gov/bank/
individual/failed/banklist.html or
contact the Manager of Receivership
Oversight in the appropriate service
center.
Dated: December 19, 2011.
Federal Deposit Insurance Corporation.
Pamela Johnson,
Regulatory Editing Specialist.
INSTITUTIONS IN LIQUIDATION
[In Alphabetical Order]
FDIC ref. No.
Bank name
City
10415 ....................................
10416 ....................................
Premier Community Bank of the Emerald Coast ..............
Western National Bank ......................................................
Crestview .............................
Phoenix ................................
[FR Doc. 2011–33020 Filed 12–23–11; 8:45 am]
BILLING CODE 6714–01–P
FEDERAL RESERVE SYSTEM
sroberts on DSK5SPTVN1PROD with NOTICES
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The application also will be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
VerDate Mar<15>2010
22:00 Dec 23, 2011
Jkt 226001
Governors not later than January 23,
2012.
A. Federal Reserve Bank of Kansas
City (Dennis Denney, Assistant Vice
President) 1 Memorial Drive, Kansas
City, Missouri 64198–0001:
1. Central Financial Corporation,
Hutchinson, Kansas, to acquire an
additional .25 percent, for a total of 7.05
percent, of the voting shares of TTAC
Corp., and thereby indirectly acquire
additional voting shares of Community
First National Bank, both in Manhattan,
Kansas.
Board of Governors of the Federal Reserve
System, December 21, 2011.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. 2011–33096 Filed 12–23–11; 8:45 am]
BILLING CODE 6210–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Request for Nominations of
Candidates To Serve on the Advisory
Committee on Breast Cancer in Young
Women (ACBCYW)
The CDC is soliciting nominations for
membership on the ACBCYW. The
Committee provides advice and
guidance to the Secretary, HHS; the
Assistant Secretary for Health; and the
Director, CDC, regarding the formative
research, development, implementation
and evaluation of evidence-based
activities designed to prevent breast
cancer (particularly among those at
heightened risk) and promote the early
detection and support of young women
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
State
FL
AZ
Date closed
12/16/2011
12/16/2011
who develop the disease. The advice
provided by the Committee will assist in
ensuring scientific quality, timeliness,
utility, and dissemination of credible
appropriate messages and resource
materials.
Nominations are being sought for
individuals who have expertise and
qualifications necessary to contribute to
the accomplishments of the committee’s
objectives. The Secretary, HHS, acting
through the Director, CDC, shall appoint
to the advisory committee nominees
with expertise in breast cancer, disease
prevention, early detection, diagnosis,
public health, social marketing, genetic
screening and counseling, treatment,
rehabilitation, palliative care, and
survivorship in young women, or in
related disciplines with a specific focus
on young women. Members may be
invited to serve for up to four years. The
next cycle of selection of candidates
will begin in the winter of 2012, for
selection of potential nominees to
replace members whose terms will end
on October 15, 2012 and October 15,
2013 respectively.
Selection of members is based on
candidates’ qualifications to contribute
to the accomplishment of ACBCYW
objectives https://www.cdc.gov/maso/
FACM/facmACBCYW.htm. The U.S.
Department of Health and Human
Services will give close attention to
equitable geographic distribution and to
minority and female representation so
long as the effectiveness of the
Committee is not impaired.
Appointments shall be made without
discrimination on the basis of age, race,
ethnicity, gender, sexual orientation,
HIV status, disability, and cultural,
religious, or socioeconomic status.
Consideration is given to a broad
E:\FR\FM\27DEN1.SGM
27DEN1
sroberts on DSK5SPTVN1PROD with NOTICES
80946
Federal Register / Vol. 76, No. 248 / Tuesday, December 27, 2011 / Notices
representation of geographic areas
within the U.S., with diverse
representation of both genders, ethnic
and racial minorities, and persons with
disabilities. Nominees must be U.S.
citizens, and cannot be full-time
employees of the U.S. Government.
Candidates should submit the
following items:
• Current curriculum vitae or resume,
including complete contact information
(name, affiliation, mailing address,
telephone numbers, fax number, email
address);
• A 150 word biography for the
nominee;
• At least one letter of
recommendation from a person(s) not
employed by the U.S. Department of
Health and Human Services. Candidates
may submit letter(s) from current HHS
employees if they wish, but at least one
letter must be submitted by a person not
employed by HHS.
Nominations should be submitted
(postmarked or received) by January 25,
2012.
• Electronic submission: You may
submit nominations, including
attachments, electronically to
acbcyw@cdc.gov.
• Regular, Express or Overnight Mail:
Written nominations may be submitted
to the following addressee only:
Temeika L. Fairley, Ph.D., c/o ACBCYW
Designated Federal Officer, CDC, 4770
Buford Highway NE., Mailstop K–52,
Atlanta, Georgia 30341.
Telephone and facsimile submissions
cannot be accepted. Nominations may
be submitted by the candidate or by the
person/organization recommending the
candidate.
Candidates invited to serve will be
asked to submit the ‘‘Confidential
Financial Disclosure Form for Special
Government Employees Serving on
Federal Advisory Committees at the
Centers for Disease Control and
Prevention.’’ This form allows CDC to
determine whether there is a statutory
conflict between that person’s public
responsibilities as a Special Government
Employee and private interests and
activities, or the appearance of a lack of
impartiality, as defined by Federal
regulation. The form may be viewed and
downloaded at https://www.usoge.gov/
forms/oge450_pdf/
oge450_accessible.pdf. This form
should not be submitted as part of the
nomination.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and the
VerDate Mar<15>2010
22:00 Dec 23, 2011
Jkt 226001
Agency for Toxic Substances and
Disease Registry.
Dated: December 20, 2011.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2011–33092 Filed 12–23–11; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0915]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Guidance for
Industry on Postmarketing Adverse
Event Reporting for Nonprescription
Human Drug Products Marketed
Without an Approved Application
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the Agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal Agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
the FDA guidance for industry on
‘‘Postmarketing Adverse Event
Reporting for Nonprescription Human
Drug Products Marketed Without an
Approved Application.’’ This guidance
document provides recommendations
on postmarketing serious adverse event
reporting for nonprescription (over-thecounter) human drugs marketed without
an approved application. It provides
recommendations on the minimum data
elements that should be included in a
serious adverse event report, the label
that should be included with the report,
reporting formats for paper and
electronic submissions, and how and
where to submit the reports.
DATES: Submit either electronic or
written comments on the collection of
information by February 27, 2012.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
SUMMARY:
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Juanmanuel Vilela, Office of
Information Management, Food and
Drug Administration, 1350 Piccard Dr.
PI50–400B, Rockville, MD 20850, (301)
796–7651,
juanmanuel.vilela@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Guidance for Industry on
Postmarketing Adverse Event Reporting
for Nonprescription Human Drug
Products Marketed Without an
Approved Application—(OMB Control
Number 0910–0636)—Extension
Respondents to this collection of
information are manufacturers, packers,
and distributors whose name (under
E:\FR\FM\27DEN1.SGM
27DEN1
]]>Agencies
[Federal Register Volume 76, Number 248 (Tuesday, December 27, 2011)]
[Notices]
[Pages 80945-80946]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-33092]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Request for Nominations of Candidates To Serve on the Advisory
Committee on Breast Cancer in Young Women (ACBCYW)
The CDC is soliciting nominations for membership on the ACBCYW. The
Committee provides advice and guidance to the Secretary, HHS; the
Assistant Secretary for Health; and the Director, CDC, regarding the
formative research, development, implementation and evaluation of
evidence-based activities designed to prevent breast cancer
(particularly among those at heightened risk) and promote the early
detection and support of young women who develop the disease. The
advice provided by the Committee will assist in ensuring scientific
quality, timeliness, utility, and dissemination of credible appropriate
messages and resource materials.
Nominations are being sought for individuals who have expertise and
qualifications necessary to contribute to the accomplishments of the
committee's objectives. The Secretary, HHS, acting through the
Director, CDC, shall appoint to the advisory committee nominees with
expertise in breast cancer, disease prevention, early detection,
diagnosis, public health, social marketing, genetic screening and
counseling, treatment, rehabilitation, palliative care, and
survivorship in young women, or in related disciplines with a specific
focus on young women. Members may be invited to serve for up to four
years. The next cycle of selection of candidates will begin in the
winter of 2012, for selection of potential nominees to replace members
whose terms will end on October 15, 2012 and October 15, 2013
respectively.
Selection of members is based on candidates' qualifications to
contribute to the accomplishment of ACBCYW objectives https://www.cdc.gov/maso/FACM/facmACBCYW.htm. The U.S. Department of Health and
Human Services will give close attention to equitable geographic
distribution and to minority and female representation so long as the
effectiveness of the Committee is not impaired. Appointments shall be
made without discrimination on the basis of age, race, ethnicity,
gender, sexual orientation, HIV status, disability, and cultural,
religious, or socioeconomic status. Consideration is given to a broad
[[Page 80946]]
representation of geographic areas within the U.S., with diverse
representation of both genders, ethnic and racial minorities, and
persons with disabilities. Nominees must be U.S. citizens, and cannot
be full-time employees of the U.S. Government.
Candidates should submit the following items:
Current curriculum vitae or resume, including complete
contact information (name, affiliation, mailing address, telephone
numbers, fax number, email address);
A 150 word biography for the nominee;
At least one letter of recommendation from a person(s) not
employed by the U.S. Department of Health and Human Services.
Candidates may submit letter(s) from current HHS employees if they
wish, but at least one letter must be submitted by a person not
employed by HHS.
Nominations should be submitted (postmarked or received) by January
25, 2012.
Electronic submission: You may submit nominations,
including attachments, electronically to acbcyw@cdc.gov.
Regular, Express or Overnight Mail: Written nominations
may be submitted to the following addressee only: Temeika L. Fairley,
Ph.D., c/o ACBCYW Designated Federal Officer, CDC, 4770 Buford Highway
NE., Mailstop K-52, Atlanta, Georgia 30341.
Telephone and facsimile submissions cannot be accepted. Nominations
may be submitted by the candidate or by the person/organization
recommending the candidate.
Candidates invited to serve will be asked to submit the
``Confidential Financial Disclosure Form for Special Government
Employees Serving on Federal Advisory Committees at the Centers for
Disease Control and Prevention.'' This form allows CDC to determine
whether there is a statutory conflict between that person's public
responsibilities as a Special Government Employee and private interests
and activities, or the appearance of a lack of impartiality, as defined
by Federal regulation. The form may be viewed and downloaded at https://www.usoge.gov/forms/oge450_pdf/oge450_accessible.pdf. This form
should not be submitted as part of the nomination.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and the Agency for Toxic
Substances and Disease Registry.
Dated: December 20, 2011.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2011-33092 Filed 12-23-11; 8:45 am]
BILLING CODE 4163-18-P
